ZENTALIS PHARMACEUTICALS INC
ZENTALIS PHARMACEUTICALS INC
Share · US98943L1070 · ZNTL (XNAS)
Overview Financial Indicators
1,53 USD
7,67 % 0,11 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 21:32

Current Prices from ZENTALIS PHARMACEUTICALS INC

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ZNTL
USD
06.06.2025 21:32
1,53 USD
1,47 USD
+4,08 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 26,45 % 22,40 % -20,73 % -56,29 % -86,19 % -96,64 %

Company Profile for ZENTALIS PHARMACEUTICALS INC Share

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Invested Funds

The following funds have invested in: ZENTALIS PHARMACEUTICALS INC invested:

Fund
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in million
88,86
Percentage (%)
0,21 %

Company Data

Name ZENTALIS PHARMACEUTICALS INC
Company Zentalis Pharmaceuticals, Inc.
Symbol ZNTL
Website https://zentalis.com
Primary Exchange XNAS NASDAQ
ISIN US98943L1070
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Ms. Julie M. Eastland M.B.A.
Market Capitalization 95 Mio
Country United States of America
Currency USD
Employees 0,2 T
Address 1359 Broadway, 10018 New York
IPO Date 2020-04-03

Ticker Symbols

Name Symbol
NASDAQ ZNTL

More Shares

Investors who ZENTALIS PHARMACEUTICALS INC hold also have the following shares in their portfolio:
AMGEN INC
AMGEN INC Share
AUTODESK INC
AUTODESK INC Share
BARING EAST.TR.ACC.(DL)
BARING EAST.TR.ACC.(DL) Fund
CISCO SYSTEMS INC
CISCO SYSTEMS INC Share
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Share
ELECTRONIC ARTS INC
ELECTRONIC ARTS INC Share
EXP.-IMP.BK CH 17/27 MTN
EXP.-IMP.BK CH 17/27 MTN Bond
INTEL CORP
INTEL CORP Share
ISHARES INC - ISHARES MSCI GLOBAL METALS & MINING PRODUCERS ETF
ISHARES INC - ISHARES MSCI GLOBAL METALS & MINING PRODUCERS ETF ETF
JPMORGAN CHASE & CO
JPMORGAN CHASE & CO Share
MATADOR RESOURSES
MATADOR RESOURSES Share
MICROSOFT CORP
MICROSOFT CORP Share
NXP SEMICONDUCTORS NV
NXP SEMICONDUCTORS NV Share
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025